Above all, CCL18/CCL3 blockade could elicit significant antitumor effects in ESCC through preventing the infiltration of tumor-associated macrophages and proliferation of ESCC cancer cells, which might be mediated by CCL3/CCR1, CCL3/CCR5 and CCL18/PITPNM3 pathways. This evidence concerns the gene CCR1 and neoplasm.